Pharmaco-refractory chronic heart failure - the need for drug level tailored management

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10126865" target="_blank" >RIV/00179906:_____/12:10126865 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/12:10126865

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0306987712003271" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0306987712003271</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.mehy.2012.07.017" target="_blank" >10.1016/j.mehy.2012.07.017</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pharmaco-refractory chronic heart failure - the need for drug level tailored management

Popis výsledku v původním jazyce

Pharmacorefractory chronic heart failure is a serious world-wide problem of systolic dysfunction not improving despite evidence based chronic heart failure pharmacotherapy. With the aim to reverse the poor pharmacorefractory chronic heart failure prognosis, severe sophisticated technical therapeutic approaches (from cardiac resynchronization usually with implantable cardioverter-defibrillator to heart transplantation) have been clinically adopted and detached at least for the most eligible pharmacorefractory chronic heart failure patients. However, both significant limitations of these highly specialised therapeutic techniques (cost, uncertain individual effect, complication, adverse effect, waiting list) and the pharmacorefractory chronic heart failure hopelessness for unfit patients make the effort to stop the pharmacorefractory chronic heart failure genesis never ending longing. Regarding growing knowledge on differences in pharmacokinetics, authors assume that the relative undertre

Název v anglickém jazyce

Pharmaco-refractory chronic heart failure - the need for drug level tailored management

Popis výsledku anglicky

Pharmacorefractory chronic heart failure is a serious world-wide problem of systolic dysfunction not improving despite evidence based chronic heart failure pharmacotherapy. With the aim to reverse the poor pharmacorefractory chronic heart failure prognosis, severe sophisticated technical therapeutic approaches (from cardiac resynchronization usually with implantable cardioverter-defibrillator to heart transplantation) have been clinically adopted and detached at least for the most eligible pharmacorefractory chronic heart failure patients. However, both significant limitations of these highly specialised therapeutic techniques (cost, uncertain individual effect, complication, adverse effect, waiting list) and the pharmacorefractory chronic heart failure hopelessness for unfit patients make the effort to stop the pharmacorefractory chronic heart failure genesis never ending longing. Regarding growing knowledge on differences in pharmacokinetics, authors assume that the relative undertre

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Medical Hypotheses

ISSN

0306-9877

e-ISSN

—

Svazek periodika

79

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

560-563

Kód UT WoS článku

000310765300002

EID výsledku v databázi Scopus

—